You are here

Primary tabs

TransCode Therapeutics

Summary

TransCode is a pre-clinical biopharmaceutical company focused on the development and commercialization of therapeutics to treat metastatic cancer.


Fighting Metastasis with Revolutionary Therapeutics and Diagnostic Tests

TransCode Therapeutics has successfully completed animal studies with among the first therapeutics to successfully treat metastasis.

In 2018, cancer will be responsible for 9.6 million deaths globally and 90% are attributed to metastasis.

What is Metastasis?

Metastasis is when cancer spreads to a different part of the body from where it originated. Metastatic tumor cells escape into the body’s circulation, surviving transit and eventually colonizing vital organs. Virtually all cancers, including cancers of the blood and the lymphatic system (leukemia, multiple myeloma and lymphoma), can form metastatic tumors.

About TransCode Therapeutics

TransCode Therapeutics, Inc. is a pre-clinical biopharmaceutical company that is focused on the discovery, development and commercialization of a pipeline of innovative microRNA-targeted therapeutics for treating metastatic cancer.

TransCode discovered that Metastatic tumor cells depend on the over-expression of microRNA-10b to survive and metastasize.

Our founders have developed a targeted, therapeutic treatment of metastatic cancer that led to complete regression and lifetime remission after just 4-6 weeks of treatments in animals.

This innovative, powerful and promising treatment strategy eradicates metastatic cells without causing damaging effects to other parts of the body that are commonly associated with available treatment options today. Radiation and chemotherapy interferes with cell division, causing detrimental consequences to mitotically active cells such as red blood cells, cells in the skin, hair, bone marrow and intestinal lining. Our therapeutic approach spares healthy organs and has essentially no systemic toxicity, as proven in our animal studies.

9 out of 10 cancer deaths are due to metastasis. We’re working to reverse that ratio and offer a therapeutic option for patients that effectively treats their cancer.

Dr. Anna Moore
TransCode Co-Founder

Investment Opportunity

We are raising up to $36 million in order to advance our therapeutic into clinical trials to achieve Proof of Concept (POC) in humans.

The goal is to clinically assess the use of TTX-MC138 in humans in an adaptive clinical trial design, and to successfully treat patients with Stage IV cancer.

Metastasis is responsible for the majority of cancer deaths today.

9 out of 10 cancer deaths annually are due to metastasis, not the primary tumors. The therapeutic strategy developed by TransCode Therapeutics is focused on the targeting and specific eradication of metastatic tumor cells, which has proven successful in animal studies.

We are raising capital to enter the clinical trials stage so we can bring more effective treatment options to patients.

Qualified and Accredited Investors Only

Company Vision

Based on successful animal studies, we intend to create a portfolio of targeted therapeutics with potential to treat human cancers through pharmacological inactivation of specific microRNAs.

  • Metastatic tumor cells depend on over-expression of microRNA-10b to survive and metastasize (spread)
  • Inhibiting microRNA-10b → death of metastatic tumor cells → treating metastasis
  • MicroRNA-10b over-expression validated in dozens of tumor types

Transcode has developed a portfolio of targeted therapeutics addressing multiple tumor types.

  • Patented Lead therapeutic TTX-MC138 achieved POC both In Vivo & In Vitro
  • Patented Biomarker test for non-invasive detection of microRNA activity
  • To-date raised: 0.55M Seed and $5.3M NIH grants

Focus on MicroRNA-10B

To date, more than 120 studies have been completed supporting the link between microRNA-10b and cancer encompassing at least 18 cancer types, including: breast, pancreatic, lung, colorectal, gastric, bladder, ovarian, hepatocellular cancer, and others.

TransCode Therapeutics has designed the first known cancer therapeutic, TTX-MC138, that efficiently inhibits microRNA-10b in metastatic tumor cells, resulting in the regression of established metastases.

Business Model

TransCode Therapeutics intends to develop and commercialize therapeutics that target specific microRNA molecules (starting with microRNA-10b) that are dysregulated in metastasis and primary tumors.

The company intends to commercialize a platform of “molecularly targeted therapies” using its proprietary delivery system as lifelong regression treatments of these diseases.

Business Model
Develop & Commercialize a Platform of “Molecularly Targeted Therapies”
Target Specific Molecules (micoRNAs) that are Dysregulated in Metastasis
Achieve Lifelong Regression with no Recurrence in Patients with Metastasis

Investment Deck

Company Vision

To learn more about investing in TransCode Therapeutics and our breakthrough therapeutics and diagnostics, please read our investment deck.

$36 million Series A Preferred
Qualified and Accredited Investors Only

  • Clinical Trials
  • Additional patents and filings
  • Expand Management Team

Read Now

Contact

To find out more about investing
in TransCode, contact us.

Michael Dudley
Chief Executive Officer
617.470.9734
michael.dudley@transcodetherapeutics.com
TransCode Therapeutics
6 Liberty Square #2382
Boston, MA 02109
 
 

Private Placement Memorandum

Please view the Private Placement Memorandum here:

View PPM

Private Placement Memorandum

Please read the Private Placement Memorandum here: Get Private Placement Memorandum

TransCode Therapeutics product-candidates have not been evaluated or approved by the FDA or any government agency for use in humans and are still in the early stages of development.

THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT SET FORTH IN SECTION 4(a)(2) THEREOF AND RULE 506(c) OF REGULATION D PROMULGATED THEREUNDER. WE HAVE ELECTED TO SELL SECURITIES ONLY TO ACCREDITED INVESTORS AS SUCH TERM IS DEFINED IN RULE 501(a) OF REGULATION D. EACH PROSPECTIVE INVESTOR WILL BE REQUIRED TO MAKE REPRESENTATIONS AS TO THE BASIS UPON WHICH IT QUALIFIES AS AN ACCREDITED INVESTOR. PURSUANT TO RULE 506(c), INDEPENDENT VERIFICATION WILL BE REQUIRED.

THE SECURITIES OFFERED HEREBY WILL BE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. ONLY PERSONS WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT IN THE SECURITIES SHOULD PURCHASE THE SECURITIES.

THIS DOCUMENT MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.